Global pharmacogenomics project
The global pharmacogenomics project consists in establishing, through various studies including numerous international collaborations, a link between the dose of chemotherapeutic drug (in particular Busulfan) and its response in children, in order to increase its survival and improve quality of life by decreasing drug toxicity. This new individualized therapy approach allows for the identification of biomarkers to better dose a drug, taking into account the young patient’s genetics, particularly in the context of hematopoietic stem cell transplant (transplant) transplantation in children with leukemia, cancer that affects the greatest number of them (33%). This project also aims to find markers of different toxicities, such as veno-occlusive disease or graft-versus-host disease, to better individualize a treatment before starting. It has received support from the Swiss National Science Foundation.